OR WAIT null SECS
November 04, 2025
Article
Check out the latest episode of Liver Lineup on alcohol-associated liver disease, new data on resmetirom, hepatic headlines from ACG 2025, and more.
October 30, 2025
Video
Mayo explains findings from a pooled analysis of pruritus data from RESPONSE and ENHANCE highlighting seladelpar’s impact on itch in PBC.
Markov model findings showed elafibranor provided greater health benefit at a lower cost than seladelpar in ursodeoxycholic acid incomplete responders.
October 28, 2025
Njei explains the utility of Fibro-GPT for detecting advanced fibrosis and predicting hepatic decompensation in MASLD.
Real-world data suggest adding fibrates to first-line UDCA incurs several clinical benefits, including reductions in spontaneous bacterial peritonitis and hospitalizations.
October 24, 2025
Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.
October 21, 2025
View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.
October 14, 2025
Podcast
Mellinger joins Liver Lineup to discuss current shortcomings in ALD diagnosis and care, the importance of addressing underlying alcohol use disorder, and more.
October 07, 2025
High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.
October 06, 2025
The Q3 recap for hepatology spotlights key FDA news, the withdrawal of OCA for PBC, and notable hepatic research from the past few months.
